Toxicological Sciences 69, 131-138 (2002)
Copyright © 2002 by the Society of Toxicology
MOLECULAR AND GENETIC TOXICOLOGY |
Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
* Department of Safety Assessment and
Department of Safety Assessment Statistics, GlaxoSmithKline, UE0360, 709 Swedeland Road, King of Prussia, Pennsylvania 19406–0939
Troglitazone (TRO), a member of the thiazolidinedione class of drugs, has been associated with hepatotoxicity in patients. The following in vitro study was conducted to investigate the effects of TRO on mitochondrial function and viability in a human hepatoma cell line, HepG2. TRO induced a concentration- and time-dependent increase in cell death, as measured by lactate dehydrogenase release. Exposure to 50 or 100 µM TRO produced total loss of cell viability within 5 h. Preincubation of HepG2 cells with P450 inhibitors did not significantly protect against TRO-induced cell death suggesting that P450 metabolism was not required to induce cell death. Preincubation with the mitochondrial permeability transition inhibitor, cyclosporin A, provided complete protection against TRO-induced cell death. Our results also indicated that TRO produced concentration-dependent decreases in cellular ATP levels and mitochondrial membrane potential (MMP). Ultrastructural analysis demonstrated that TRO induced mitochondrial changes at concentrations of 
10 µM after 2 h. Decreased MMP and altered mitochondrial morphology occurred at time points that preceded cell death and at sublethal concentrations of TRO. These observations in HepG2 cells suggest that TRO disrupts mitochondrial function, leading to mitochondrial permeability transition and cell death.
Key Words: troglitazone; HepG2; hepatotoxicity; mitochondrial permeability transition; cyclosporin A; thiazolidinedione; ATP depletion.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Deng, J. P. Luyendyk, P. E. Ganey, and R. A. Roth Inflammatory Stress and Idiosyncratic Hepatotoxicity: Hints from Animal Models Pharmacol. Rev., September 1, 2009; 61(3): 262 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fujimoto, K. Kumagai, K. Ito, S. Arakawa, Y. Ando, S.-i. Oda, T. Yamoto, and S. Manabe Sensitivity of Liver Injury in Heterozygous Sod2 Knockout Mice Treated with Troglitazone or Acetaminophen Toxicol Pathol, February 1, 2009; 37(2): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. K. Lim, J. Liu, M. L. Go, and U. A. Boelsterli The Mitochondrial Superoxide/Thioredoxin-2/Ask1 Signaling Pathway is Critically Involved in Troglitazone-Induced Cell Injury to Human Hepatocytes Toxicol. Sci., February 1, 2008; 101(2): 341 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soller, S. Drose, U. Brandt, B. Brune, and A. von Knethen Mechanism of Thiazolidinedione-Dependent Cell Death in Jurkat T Cells Mol. Pharmacol., June 1, 2007; 71(6): 1535 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jaeschke Troglitazone Hepatotoxicity: Are We Getting Closer to Understanding Idiosyncratic Liver Injury? Toxicol. Sci., May 1, 2007; 97(1): 1 - 3. [Full Text] [PDF]
|
|
|
|
|
|
M. M.K. Ong, C. Latchoumycandane, and U. A. Boelsterli Troglitazone-Induced Hepatic Necrosis in an Animal Model of Silent Genetic Mitochondrial Abnormalities Toxicol. Sci., May 1, 2007; 97(1): 205 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-H. Cho, Y. J. Choi, S. A. Jo, J. Ryou, J. Y. Kim, J. Chung, and I. Jo Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition Am J Physiol Cell Physiol, August 1, 2006; 291(2): C317 - C326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Maniratanachote, K. Minami, M. Katoh, M. Nakajima, and T. Yokoi Chaperone Proteins Involved in Troglitazone-Induced Toxicity in Human Hepatoma Cell Lines Toxicol. Sci., February 1, 2005; 83(2): 293 - 302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. E. Kostrubsky, R. Rahbari, A. Lodola, and T. Davies Letter Toxicol. Sci., February 1, 2003; 71(2): 282 - 282. [Full Text] [PDF]
|
|
|
|
|
|
M. Tirmenstein, C. Hu, T. Gales, B. Maleeff, P. Narayanan, E. Kurali, T. Hart, H. Thomas, and L. Schwartz Reply Toxicol. Sci., February 1, 2003; 71(2): 282 - 284. [Full Text] [PDF]
|
|